|
SYRE Spyre Therapeutics Inc 1636282 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-69,005,000.00 |
| Balance Sheet |
|
Current Assets
|
$763,953,000.00 |
|
Assets
|
$763,953,000.00 |
|
Current Liabilities
|
$85,162,000.00 |
|
Liabilities
|
$93,142,000.00 |
|
Equity
|
$670,811,000.00 |
|
Shares Out
|
78839858.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-57,372,000.00 |
|
Investing Cash Flow
|
$56,581,000.00 |
| Market Analysis |
Market Cap
|
$8,002,245,587.00 |
|
Price
|
$95.15 |
|
BVPS
|
8.51 |
|
PB
|
11.93 |
|
EPS
|
-1.36 |
|
FCF
|
$-57,372,000.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:17 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:11 |
|
| Jan |
Feb |
Mar |
|
|
|
|
2026-02-19 |
-0.70 |
|
| Apr |
May |
Jun |
|
|
|
|
2026-05-05 |
-0.74 |
|
| Jul |
Aug |
Sep |
|
|
|
|
2025-08-05 |
-0.49 |
|
| Oct |
Nov |
Dec |
|
|
|
|
2025-11-04 |
-0.15 |
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view SYRE documents filed with the SEC.
SYRE Filings
Clear
